The Lead Episode 178: A Discussion of Safety and Performance of a Novel ICD Lead for Left Bundle Branch Area Pacing
Availability
On-Demand
Expires on Nov 16, 2029
Cost
$0.00
Credit Offered
No Credit Offered

In this episode of The Lead, recorded live at HRX 2026, host Michael S. Lloyd, MD, FHRS, of Emory University, is joined by Dominik K. Linz, MD, PhD, of Maastricht University Medical Center, and Ashish A. Bhimani, BSE, MD, FHRS, of Piedmont Heart Institute, to discuss the article “Safety and performance of a novel ICD lead for left bundle branch area pacing: Results from the ASCEND CSP trial,” published in Heart Rhythm. The panel examines the study's findings on implantation success, pacing and sensing performance, defibrillation effectiveness, and procedural safety, while exploring concerns about long-term lead durability, tricuspid valve interactions, and the potential role of conduction system pacing in patients requiring defibrillator therapy.

  1. Describe the design, patient population, and primary safety and effectiveness outcomes of the ASCEND CSP trial evaluating a novel ICD lead for left bundle branch area pacing.

  2. Evaluate the performance of the novel ICD lead, including implantation success, conduction system capture, pacing and sensing thresholds, defibrillation testing, and procedure-related complications.

  3. Assess the potential clinical applications and long-term limitations of combining conduction system pacing and defibrillation capabilities in a single lead, including concerns related to tricuspid valve function, lead extraction, and durability.


Podcast Contributors

Host: 

Michael S. Lloyd, MD, FHRS | Emory University

 

Guests: 

Dominik K Linz, MD, PhD | Maastricht University Medical Center

Ashish A. Bhimani, BSE, MD, FHRS | Piedmont Heart Institute

 

 

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

M. Lloyd
  • Honoraria/Speaking/Consulting Fee: Medtronic
  • Membership on Advisory Committee: Boston Scientific, ABIM


D. Linz

  • Nothing to disclose


A. Bhimani

  • Honoraria/Speaking/Consulting Fee: Boston Scientific, Biotronik, St. Jude Medical, Medtronic, Pacemate




Staff Disclosu
re(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.
M. Baldwin: No relevant financial relationships with ineligible companies to disclose.